Mitigating MS DMT Infection Risk

Volume 5, Issue 6

Mitigating MS DMT Infection Risk

In this issue:

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should clinicians do about it? What do the data say?

Join us, as Dr. Le Hua and Dr. Areeba Siddiqui from the Cleveland Clinic’s Lou Ruvo Center for Brain Health explore these questions in this issue of eMultipleSclerosis Review.

Learning objectives:

Identify infection risks associated with B-cell therapies and describe appropriate mitigation strategies.
Describe the risk of lymphopenia associated with various DMTs, related risks of infection, and an outline to decrease those risks.

Authors:

Le H. Hua, MD

Professor of Neurology
Director, Multiple Sclerosis Section
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV

Areeba Siddiqui, MD

Fellow, Multiple Sclerosis and Neuroimmunology
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV

Guest Faculty Disclosures

Dr. Hua has disclosed that she has served as an advisor for EMD Serono and Novartis AG and received grant/research support from Biogen Idec. Dr. Siddiqui has indicated that she has no financial interests in or relationships with a commercial entity.

Unlabeled/Unapproved Uses

Dr. Hua and Dr. Siddiqui have indicated that they will reference the off-label intervals for natalizumab and B cell monoclonal antibodies; S1P1 modulators may be discussed as risk-mitigation strategies.

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures:

Unlabeled/Unapproved Uses:

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: August 2, 2023
Expiration date: August 1, 2025

Start Issue